Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese

Pharmacogenetics

Volumn 9, Issue 3, 1999, Pages 401-404

  Katoh, Takahiko ^a   Inatomi, Hisato ^b   Yang, Mihi ^c   Kawamoto, Toshihiro ^c   Matsumoto, Tetsuro ^b   Bell, Douglas A ^d  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Department of Urology ^*  (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

N acetyltransferase 1; N acetyltransferase 2; Polymorphism; Urothelial cancer

Indexed keywords

AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA ADDUCT; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRANSITIONAL CELL CARCINOMA;

EID: 0032810707     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199906000-00017     Document Type: Article

References (17)

1. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine transferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 1995; 55:5230-5237.
2. Bell DA, Taylor JA, Butler MA, Stephens E, Wiest J, Brubaker L, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993; 14:1689-1692.
3. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995a; 55:5226-5229.
4. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson MA, Deakin M, et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995b; 55:3537-3542.
5. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990; 9:193-203.
6. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in human. Proc Natl Acad Sci USA 1991; 88:5237-5241.
7. Bourchardy C, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, Dayer P, Benhamou S, Hirvonen A. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998; 8:291-298.
8. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham Hall D, Higgins E, Kahn MA. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982; 2:842-846.
9. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, et al. Human acetyltransferase polymorphisms. Mutat Res 1997; 376:61-70.
10. Grant DM, Hughes NC, Janezic SA, Sampson H, Darlington G, Jewett MA. Interindividual variation in cytochrome P4501A2, acetyltransferases NAT1 and NAT2 and risk for bladder cancer: a case-control study. Proc Am Assoc Cancer Res 1998; 39:455.
11. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, Grant DM. Metabolic activation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14:1633-1638.
12. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA. A pilot study testing the association between N-acetyltransferases 1 (NAT1) and 2 (NAT2) and risk of oral squamous cell carcinoma in Japanese. Carcinogenesis 1998; 19:1803-1807.
13. Lin HJ, Probst-Hensch NM, Hughes NC, Sakamoto GT, Louie AD, Kau IH, et al. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics 1998; 8:269-281.
14. Ohsako S, Deguchi T. Cloning and expression of cDNA for polymorphic and monomorphic arylamine N-acetyltransferase from human liver. J Biol Chem 1990; 265:4630-4634.
15. Okkels H, Sigsgaard T, Wolf H, Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomark Prev 1997; 6:225-231.
16. Taylor JA, Umbach D, CastranioT, Stephens E, Paulson D, Robertson D, et al. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene exposure three-way interaction. Cancer Res 1998; 58:3603-3610.
17. Vineis P. Epidemiology of cancer from exposure to arylamines. Environ Health Perspect 1994; 102 (Suppl.6):7-10.